Visionary psychedelic researcher reshapes treatment landscape for psychiatric disorders

(Press-News.org) NEW YORK, New York, USA, 10 June 2025 – In a comprehensive Genomic Press Interview published today, Dr. Stephen Ross, a leading figure in psychedelic medicine at New York University (NYU), reveals how a serendipitous conversation in 2006 launched his journey into investigating psychedelic compounds as potential breakthrough treatments for some of psychiatry's most challenging conditions.

Rediscovering a forgotten therapeutic approach

"Hidden in plain sight," as Dr. Ross describes it, was an extensive body of research from the 1950s to 1970s involving over 40,000 participants and 1,000 published articles exploring the therapeutic potential of psychedelics. This promising research direction effectively disappeared from psychiatric education and practice following prohibition in 1970.

"Nowhere in my training, ranging from medical school to general psychiatry residency to addiction fellowship training, did I ever hear about this very interesting and significant part of psychiatric history," notes Dr. Ross in the interview. His curiosity about this overlooked research area led to the formation of the NYU Psychedelic Research Group in 2006, helping to spark what he calls "the second wave of psychedelic research."

Breakthrough findings in cancer-related distress

Among Dr. Ross's most significant contributions was a landmark 2016 randomized controlled trial assessing the efficacy of psilocybin-assisted psychotherapy for anxiety, depression, and existential distress in patients with advanced cancer. The study results, which received extensive international coverage and was featured on the front page of the New York Times, demonstrated rapid, substantial, and sustained improvements in psychological symptoms.

"I was shocked at the results of this trial, not expecting such rapid and robust clinical responses," Dr. Ross explains. The treatment not only reduced anxiety and depression but also improved quality of life and reduced existential distress. Approximately 75% of participants rated their psilocybin experience as one of the most meaningful and memorable experiences of their lives.

What makes these findings particularly remarkable? How might these rapid and sustained effects from a single treatment session challenge our current understanding of psychiatric medication, which typically requires daily administration over extended periods?

Expanding therapeutic frontiers

Building on this success, Dr. Ross has expanded his research to include substance use disorders, with promising results from a trial using psilocybin to treat alcohol use disorder, published in JAMA Psychiatry in 2022. This study demonstrated significant reductions in heavy drinking days over an eight-month period following just two doses of psilocybin combined with psychotherapy.

Could psychedelic therapy represent a paradigm shift in addiction treatment, an area where conventional approaches have shown limited effectiveness? What neurobiological mechanisms might explain these sustained effects from limited dosing?

Dr. Ross is also investigating psilocybin's potential in treating major depressive disorder (MDD). As senior author on a phase 2 multi-center trial published in JAMA in 2023, he and colleagues demonstrated that single-dose psilocybin-assisted psychotherapy produced rapid, clinically significant, and sustained reductions in depressive symptoms.

The future of psychedelic medicine

Currently, Dr. Ross is leading an NIH-funded clinical trial, the largest to date, examining psilocybin therapy for cancer-related emotional and spiritual distress. This represents a significant milestone as one of the first NIH grants for psychedelic research in over 50 years. He's also expanding into new therapeutic areas, including fear of recurrence in early-stage breast cancer patients and exploring psychedelics for chronic pain management.

What implications might the mainstreaming of psychedelic therapy have for psychiatric care delivery systems? How might these treatments be integrated into cancer centers, palliative care programs, and addiction treatment facilities if approved?

Dr. Ross's journey hasn't been without obstacles. When he first embarked on psychedelic research, several mentors warned him it was "a road to nowhere" and "a career killer." His persistence in the face of these challenges underscores the potential significance of this therapeutic approach.

Dr. Stephen Ross's Genomic Press interview is part of a larger series called Innovators & Ideas that highlights the people behind today's most influential scientific breakthroughs. Each interview in the series offers a blend of cutting-edge research and personal reflections, providing readers with a comprehensive view of the scientists shaping the future. By combining a focus on professional achievements with personal insights, this interview style invites a richer narrative that both engages and educates readers. This format provides an ideal starting point for profiles that delve into the scientist's impact on the field, while also touching on broader human themes. More information on the research leaders and rising stars featured in our Innovators & Ideas – Genomic Press Interview series can be found in our publications website: https://genomicpress.kglmeridian.com/.

The Genomic Press Interview in Psychedelics titled "Stephen Ross: Psychedelic-assisted therapies for difficult-to-treat psychiatric and medical disorders," is freely available via Open Access on 27 May 2025 in Psychedelics at the following hyperlink: https://doi.org/10.61373/pp025k.0017.

About Psychedelics: Psychedelics: The Journal of Psychedelic and Psychoactive Drug Research (ISSN: 2997-2671, online and 2997-268X, print) is a peer reviewed medical research journal published by Genomic Press, New York. Psychedelics is dedicated to advancing knowledge across the full spectrum of consciousness altering substances, from classical psychedelics to stimulants, cannabinoids, entactogens, dissociatives, plant derived compounds, and novel compounds including drug discovery approaches. Our multidisciplinary approach encompasses molecular mechanisms, therapeutic applications, neuroscientific discoveries, and sociocultural analyses. We welcome diverse methodologies and perspectives from fundamental pharmacology and clinical studies to psychological investigations and societal-historical contexts that enhance our understanding of how these substances interact with human biology, psychology, and society.

Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/

Our full website is at: https://genomicpress.kglmeridian.com/

END